Endoplasmic Reticulum Stress and Parkinson's Disease

内质网应激与帕金森病

基本信息

  • 批准号:
    6625903
  • 负责人:
  • 金额:
    $ 18.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-02-01 至 2005-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant) Recent observations suggest that abnormal conformations of proteins that are normal constituents of the dopaminergic neuron participate in death of this cell type in Parkinson Disease (PD). Some rare forms of PD can be linked to mutations that cause such proteotoxicity, either directly by affecting the primary structure of the protein converting it to a proteotoxin (e.g. a-SYN mutations) or indirectly, by affecting cellular processes that impact on the accumulation of proteotoxins (e.g. PARK2 mutations). However, such mutations are found in only a small fraction of PD patients, raising the question of how proteotoxicity is triggered in other cases. Recent experiments from our lab indicate that 6-hydroxydopamine and Rotenone, toxins implicated in experimental and environmental PD, cause an imbalance between the folding capacity of the endoplasmic reticulum (ER) and the load of client proteins placed on that organelle (so called ER stress). Uncompensated ER stress can promote proteotoxicity by competing for limited capacity of the ubiquitin proteasomal system and by producing ROS that can alter protein structure. Neurons are naturally prone to ER stress because of their extensive secretory activity and because of their highly elaborate membrane enclosed processes, which must be maintained by high rates of ER trafficking of client proteins. ER stress is normally counteracted by the unfolded protein response (UPR), an adaptive cellular signaling pathway that is activated specifically by ER stress. Impaired UPR signaling sensitizes cells specifically to the effect of ER stress. Therefore, we propose to test the role of ER stress in the development of PD by examining the effect of mutations that impair signaling in the UPR on an established model of experimental PD and on a component of genetic PD. We will determine if in mice lacking the key UPR gene, PERK dopaminergic neurons are hypersensitive to 6-hydroxydopamine. We will seek to identify the defect in ER function imparted by 6-hydroxydopamine and relate it, if possible, to the known ability of the toxin to inhibit mitochondrial complex-1. Finally, we will critically examine PARK2's role in ER-associated degradation of proteins. If the proposed experiments support a role for ER stress in the development of PD, this will effect a paradigmatic shift in our thinking about the pathogenesis of this common disorder.
描述(由申请人提供) 最近的观察表明,蛋白质的异常构象, 多巴胺能神经元的正常成分参与这种死亡。 帕金森病(PD)的细胞类型。一些罕见的PD形式可能与 突变,导致这种蛋白毒性,无论是直接影响 蛋白质的一级结构将其转化为蛋白毒素(例如a-SYN 突变)或间接地,通过影响细胞过程, 蛋白毒素的积累(例如PARK 2突变)。然而,这种突变 仅在一小部分PD患者中发现,这引发了一个问题: 蛋白毒性在其他情况下被触发。我们实验室最近的实验 表明6-羟基多巴胺和鱼藤酮,实验中涉及毒素 和环境PD,导致折叠能力之间的不平衡, 内质网(ER)和置于其上的客户蛋白质负载 细胞器(所谓的ER应激)。未补偿的内质网应激可以促进 通过竞争泛素蛋白酶体的有限能力的蛋白毒性 系统和产生ROS,可以改变蛋白质结构。神经元是 由于其广泛的分泌活性, 由于它们高度复杂的膜封闭过程, 通过客户蛋白的高ER运输率维持。ER应力是 通常由未折叠蛋白质反应(UPR)抵消,适应性 细胞信号通路,特别是激活内质网应激。 受损的UPR信号传导使细胞特异性地对ER的作用敏感 应力因此,我们建议测试ER应激在发育中的作用, 通过检查损害UPR信号传导的突变对PD的影响, 建立实验性PD模型和遗传性PD的一个组成部分。我们 将确定在缺乏关键UPR基因的小鼠中, 对6-羟多巴胺过敏我们会设法找出 6-羟基多巴胺赋予的ER功能,如果可能的话, 该毒素抑制线粒体复合物-1的已知能力。最后我们将 严格检查PARK 2在ER相关蛋白质降解中的作用。如果 所提出的实验支持ER应激在PD发展中的作用, 这将影响我们对糖尿病发病机制的思维范式转变, 这种常见的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID RON其他文献

DAVID RON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID RON', 18)}}的其他基金

Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7996470
  • 财政年份:
    2009
  • 资助金额:
    $ 18.38万
  • 项目类别:
Screening for Inhibitors of the Integrated Stress Response
综合应激反应抑制剂的筛选
  • 批准号:
    7365462
  • 财政年份:
    2007
  • 资助金额:
    $ 18.38万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7263952
  • 财政年份:
    2006
  • 资助金额:
    $ 18.38万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7458067
  • 财政年份:
    2006
  • 资助金额:
    $ 18.38万
  • 项目类别:
Drug-like small molecule modulators of Integrated Stress
综合应激的类药物小分子调节剂
  • 批准号:
    7124080
  • 财政年份:
    2006
  • 资助金额:
    $ 18.38万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7638527
  • 财政年份:
    2006
  • 资助金额:
    $ 18.38万
  • 项目类别:
Endoplasmic Reticulum Stress and Parkinson's Disease
内质网应激与帕金森病
  • 批准号:
    6835944
  • 财政年份:
    2002
  • 资助金额:
    $ 18.38万
  • 项目类别:
Endoplasmic Reticulum Stress and Parkinson's Disease
内质网应激与帕金森病
  • 批准号:
    6479891
  • 财政年份:
    2002
  • 资助金额:
    $ 18.38万
  • 项目类别:
ADIPOCYTE GROWTH AND PATHOGENESIS OF LIPOSARCOMA
脂肪细胞的生长和脂肪肉瘤的发病机制
  • 批准号:
    6376022
  • 财政年份:
    1997
  • 资助金额:
    $ 18.38万
  • 项目类别:
ADIPOCYTE GROWTH AND PATHOGENESIS OF LIPOSARCOMA
脂肪细胞的生长和脂肪肉瘤的发病机制
  • 批准号:
    2895058
  • 财政年份:
    1997
  • 资助金额:
    $ 18.38万
  • 项目类别:

相似海外基金

Manipulation and engineering of lipid metabolic pathways in CHO cells to enhance processability of cell culture supernantants
CHO 细胞中脂质代谢途径的操作和工程,以增强细胞培养上清液的可加工性
  • 批准号:
    2873335
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Studentship
Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin
CHO细胞的糖工程表达重组α-1抗胰蛋白酶
  • 批准号:
    10484110
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
Evaluation of antibody-heterogeneity in CHO cells
CHO 细胞中抗体异质性的评估
  • 批准号:
    20K15105
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidating the signalling pathways important for antibody production and secretion in CHO cells
阐明 CHO 细胞中抗体产生和分泌的重要信号通路
  • 批准号:
    2467836
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Studentship
Combinatorial approaches to engineer CHO cells to enhance production of difficult-to-express therapeutic proteins
改造 CHO 细胞的组合方法以增强难以表达的治疗性蛋白质的产生
  • 批准号:
    BB/T508615/1
  • 财政年份:
    2019
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Training Grant
Development of rapid production of antibody drugs using a single-copy gene expression system in CHO cells
开发利用 CHO 细胞单拷贝基因表达系统快速生产抗体药物
  • 批准号:
    19K05178
  • 财政年份:
    2019
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Utilization of chromosomal instability in CHO cells in recombinant protein production
在重组蛋白生产中利用 CHO 细胞染色体不稳定性
  • 批准号:
    19K21105
  • 财政年份:
    2018
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of a novel inducible expression system for the manufacture of therapeutic proteins from CHO cells.
开发一种新型诱导表达系统,用于从 CHO 细胞生产治疗性蛋白质。
  • 批准号:
    104199
  • 财政年份:
    2018
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Collaborative R&D
Developing novel biosensors for monitoring antibody production in CHO cells.
开发新型生物传感器来监测 CHO 细胞中抗体的产生。
  • 批准号:
    1983469
  • 财政年份:
    2018
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Studentship
Cell and Process Engineering for Transient Expression of Recombinant Proteins in CHO Cells
CHO 细胞中重组蛋白瞬时表达的细胞和工艺工程
  • 批准号:
    2122943
  • 财政年份:
    2018
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了